Trial reportNature communications2026
Multidisciplinary intervention in frail elderly patients with cardiovascular diseases: a multicentre, single-blinded, randomised controlled trial.
Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Evidence supporting multidisciplinary interventions for frailty in elderly cardiovascular inpatients remains limited. In this completed multicentre, single-blinded, randomised controlled trial (ChiCTR1900022623), 333 frail inpatients aged ≥ 70 years with cardiovascular diseases were randomly assigned to RENAP (Rehabilitation exercises, patient Education, Nutritional guidance, Acupoint massage, and Polypharmacy management) programme (n = 166) or usual care (n = 167). The trial was supported by grants from the Beijing Municipal Science and Technology Commission and the Chinese Academy of Medical Sciences. The primary outcomes were changes from baseline to 12 months in Fried Frailty Phenotype (FFP) and Short Physical Performance Battery (SPPB) scores at one year. RENAP significantly improved FFP score [t(993) = -4.79; P < 0.001; adjusted mean difference -0.79; 95% CI: -1.11 to -0.46] and SPPB score [t(993) = 4.06; P < 0.001; adjusted mean difference 2.02; 95% CI: 1.04 to 2.99]. No treatment-related serious adverse events were observed during the study. These findings suggest that a hospital-initiated multidisciplinary programme may improve frailty and physical function in frail elderly adults with cardiovascular diseases. The single-city setting and loss to follow-up may limit generalisability and warrant confirmation in broader healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.